Fecal transplantation for treatment of inflammatory bowel disease.

Related Articles Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2018 Nov 13;11:CD012774 Authors: Imdad A, Nicholson MR, Tanner-Smith EE, Zackular JP, Gomez-Duarte OG, Beaulieu DB, Acra S Abstract BACKGROUND: Inflammatory bowel disease (IBD) is a chronic, relapsing disease of the gastrointestinal tract that is thought to be associated with a complex interplay between microbes and the immune system, leading to an abnormal inflammatory response in genetically susceptible individuals. Dysbiosis, characterized by the alteration of the composition of the resident commensal bacteria in a host compared…

Read More

Cannabis for the treatment of Crohn’s disease.

Cannabis for the treatment of Crohn’s disease. Cochrane Database Syst Rev. 2018 Nov 08;11:CD012853 Authors: Kafil TS, Nguyen TM, MacDonald JK, Chande N Abstract BACKGROUND: Crohn’s disease (CD) is a chronic immune-mediated condition of transmural inflammation in the gastrointestinal tract, associated with significant morbidity and decreased quality of life. The endocannabinoid system provides a potential therapeutic target for cannabis and cannabinoids and animal models have shown benefit in decreasing inflammation. However, there is also evidence to suggest transient adverse events such as weakness, dizziness and diarrhea, and an increased risk…

Read More

Cannabis for the treatment of ulcerative colitis.

Cannabis for the treatment of ulcerative colitis. Cochrane Database Syst Rev. 2018 Nov 08;11:CD012954 Authors: Kafil TS, Nguyen TM, MacDonald JK, Chande N Abstract BACKGROUND: Cannabis and cannabinoids are often promoted as treatment for many illnesses and are widely used among patients with ulcerative colitis (UC). Few studies have evaluated the use of these agents in UC. Further, cannabis has potential for adverse events and the long-term consequences of cannabis and cannabinoid use in UC are unknown. OBJECTIVES: To assess the efficacy and safety of cannabis and cannabinoids for the…

Read More

Psychological therapies for the management of chronic and recurrent pain in children and adolescents.

Related Articles Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2018 Sep 29;9:CD003968 Authors: Fisher E, Law E, Dudeney J, Palermo TM, Stewart G, Eccleston C Abstract BACKGROUND: This is an update of the original Cochrane review first published in Issue 1, 2003, and previously updated in 2009, 2012 and 2014. Chronic pain, defined as pain that recurs or persists for more than three months, is common in childhood. Chronic pain can affect nearly every aspect of daily life and…

Read More

Enteral nutrition for maintenance of remission in Crohn’s disease.

Related Articles Enteral nutrition for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018 Aug 11;8:CD005984 Authors: Akobeng AK, Zhang D, Gordon M, MacDonald JK Abstract BACKGROUND: Prevention of relapse is a major issue in the management of quiescent Crohn’s disease (CD). Current therapies (e.g. methotrexate, biologics, 6-mercaptopurine and azathioprine) may be effective for maintaining remission in CD, but these drugs may cause significant adverse events. Interventions that are effective and safe for maintenance of remission in CD are desirable. OBJECTIVES: The primary objectives were to evaluate the…

Read More

Natalizumab for induction of remission in Crohn’s disease.

Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018 Aug 01;8:CD006097 Authors: Nelson SM, Nguyen TM, McDonald JW, MacDonald JK Abstract BACKGROUND: This systematic review update summarizes the current evidence on the use of natalizumab for induction of remission in Crohn’s disease (CD). OBJECTIVES: To determine the efficacy and safety of natalizumab for induction of remission in CD. SEARCH METHODS: We searched MEDLINE, Embase, CENTRAL, the Cochrane IBD Group Specialized Trials Register, and clinicaltrials.gov from inception to 10 May 2018. SELECTION CRITERIA: We included randomized controlled…

Read More

Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn’s disease.

Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn’s disease. Cochrane Database Syst Rev. 2018 May 12;5:CD012540 Authors: Boyapati RK, Torres J, Palmela C, Parker CE, Silverberg OM, Upadhyaya SD, Nguyen TM, Colombel JF Abstract BACKGROUND: Crohn’s disease (CD) is a chronic, relapsing and remitting disease of the gastrointestinal tract that can cause significant morbidity and disability. Current treatment guidelines recommend early intervention with immunosuppressant or biological therapy in high-risk patients with a severe disease phenotype at presentation. The feasibility of therapeutic de-escalation once remission is achieved is…

Read More

Enteral nutritional therapy for induction of remission in Crohn’s disease.

Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018 Apr 01;4:CD000542 Authors: Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M Abstract BACKGROUND: Corticosteroids are often preferred over enteral nutrition (EN) as induction therapy for Crohn’s disease (CD). Prior meta-analyses suggest that corticosteroids are superior to EN for induction of remission in CD. Treatment failures in EN trials are often due to poor compliance, with dropouts frequently due to poor acceptance of a nasogastric tube and unpalatable formulations. This systematic review…

Read More

Low dose naltrexone for induction of remission in Crohn’s disease.

Low dose naltrexone for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018 Apr 01;4:CD010410 Authors: Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N Abstract BACKGROUND: Crohn’s disease is a transmural, relapsing inflammatory condition afflicting the digestive tract. Opioid signalling, long known to affect secretion and motility in the gut, has been implicated in the inflammatory cascade of Crohn’s disease. Low dose naltrexone, an opioid antagonist, has garnered interest as a potential therapy. OBJECTIVES: The primary objective was to evaluate the efficacy and safety of low…

Read More

Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis.

Related Articles Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev. 2018 Jan 16;1:CD011450 Authors: Mohammed Vashist N, Samaan M, Mosli MH, Parker CE, MacDonald JK, Nelson SA, Zou GY, Feagan BG, Khanna R, Jairath V Abstract BACKGROUND: Endoscopic assessment of mucosal disease activity is routinely used to determine eligibility and response to therapy in clinical trials of ulcerative colitis. The operating properties of the existing endoscopic scoring indices are unclear. OBJECTIVES: A systematic review was undertaken to evaluate the development and operating characteristics…

Read More
<< Go Back